CD8A and neoplasm: (46) showed that pexidartinib, an inhibitor of CSF-1R, inhibited immune escape in solid tumors and enhanced anti-tumor activity; when pexidartinib was combined with a PD-1/PD-L1 inhibitor, CD3+CD8+ T-cell infiltration increased and M2 macrophage polarization attenuated.